EGQ0 Stock Overview
Engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
INOVIQ Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.31 |
| 52 Week High | AU$0.41 |
| 52 Week Low | AU$0.31 |
| Beta | 2.26 |
| 11 Month Change | 18.05% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -74.68% |
| 5 Year Change | -16.27% |
| Change since IPO | 4.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| EGQ0 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -4.3% | 0.3% | -0.5% |
| 1Y | n/a | -1.7% | 1.6% |
Return vs Industry: Insufficient data to determine how EGQ0 performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how EGQ0 performed against the German Market.
Price Volatility
| EGQ0 volatility | |
|---|---|
| EGQ0 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: EGQ0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine EGQ0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | n/a | Leearne Hinch | www.inoviq.com |
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers.
INOVIQ Ltd Fundamentals Summary
| EGQ0 fundamental statistics | |
|---|---|
| Market cap | €34.83m |
| Earnings (TTM) | -€4.04m |
| Revenue (TTM) | €982.40k |
35.5x
P/S Ratio-8.6x
P/E RatioIs EGQ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EGQ0 income statement (TTM) | |
|---|---|
| Revenue | AU$1.58m |
| Cost of Revenue | AU$3.26m |
| Gross Profit | -AU$1.68m |
| Other Expenses | AU$4.83m |
| Earnings | -AU$6.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.061 |
| Gross Margin | -105.79% |
| Net Profit Margin | -410.78% |
| Debt/Equity Ratio | 0% |
How did EGQ0 perform over the long term?
See historical performance and comparison